TG Therapeutics price target raised to $20 from $18 at Goldman Sachs

Goldman Sachs analyst Corinne Jenkins raised the firm’s price target on TG Therapeutics to $20 from $18 and keeps a Neutral rating on the shares after its higher than expected Q2 results and guidance raise. The firm is positive on the company’s continued momentum for the ongoing Briumvi launch whereby TG Therapeutics reported operationally positive EPS for the first time, adding that as the launch progresses, an attractive formulation of Briumvi could be a key driver of its long-term trajectory, the analyst tells investors in a research note.